Spyre Therapeutics CFO Scott Burrows sells $2.28m in shares By Investing.com

Scott L. Burrows, Chief Financial Officer of Spyre Therapeutics, Inc. (), sold common stock valued at approximately $2.28 million across multiple transactions on September 1 and September 2, 2026. Burrows also acquired shares through the exercise of stock options during the same period. The sales come after the stock delivered a remarkable 414% return over the past year, though InvestingPro analysis suggests the shares appear overvalued at current levels, landing the company on the platform’s most overvalued stocks list.

On September 1, Mr. Burrows sold a total of 7,500 shares of Spyre Therapeutics common stock for approximately $654,791. These shares were sold at prices ranging from $86.25 to $89.04 per share. These transactions were executed under a Rule 10b5-1 trading plan adopted on November 10, 2025.

On September 2, Mr. Burrows sold an additional 18,232 shares for a total of approximately $1,629,029, at an average price of $89.35 per share. This sale was made to satisfy tax withholding obligations in connection with the settlement of 33,738 restricted stock units and did not represent a discretionary trade.

Concurrently, on September 1, Mr. Burrows acquired 7,500 shares of common stock by exercising stock options at a price of $14.50 per share, totaling approximately $108,750. This option exercise was also executed pursuant to the Rule 10b5-1 trading plan. The option represents a right to purchase 404,857 shares of the Issuer’s common stock, adjusted for a 1-for-25 reverse stock split on September 8, 2023, with vesting occurring over time.

In other recent news, Spyre Therapeutics announced topline results from its Phase II SKYWAY-RA program, revealing that SPY072/TL1A showed evidence of target engagement and statistically significant efficacy improvement over placebo in rheumatoid arthritis patients. Despite these promising results, the company noted that the effect size did not support prioritizing monotherapy development, which led to a 14% decline in after-hours trading. Analysts have weighed in on these developments, with Guggenheim reiterating a Buy rating and maintaining a $130 price target, citing the program’s focus on inflammatory bowel disease (IBD). Stifel also reiterated a Buy rating with a $123 price target, though it acknowledged the study’s limited competitive effect size. Meanwhile, Wolfe Research downgraded the stock to Peerperform from Outperform, expressing concerns over valuation and potential third-quarter catalysts. On a more positive note, Mizuho raised its price target to $120, following data from the SKYLINE Part A study, which suggested high probabilities of clinical remission rates. These updates reflect the mixed reactions from analysts and the market to Spyre’s recent clinical findings.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.